Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR

Core Insights - Prenetics Global Limited has completed the divestment of ACT Genomics to Delta Electronics, marking a strategic exit from the clinical diagnostics sector to focus on consumer health initiatives [1][5] - The divestment has significantly improved Prenetics' financial position, with total proceeds from the transaction amounting to $46 million, enhancing cash reserves to over $60 million while maintaining a debt-free balance sheet [2][5] - The company is poised for growth with its flagship consumer health brand, IM8, projected to achieve an annualized revenue run-rate of $100 million within its first year [3][5] Financial Position - Prenetics received $39.9 million in cash from the $72 million transaction, with an additional $6.3 million held in escrow for future distribution [2] - The total cash reserves now exceed $60 million, excluding Bitcoin holdings, providing a strong foundation for growth [2][5] - The company maintains a debt-free balance sheet, which positions it well for future investments [2][5] Consumer Health Initiatives - IM8 is on track to become one of the fastest-growing supplement brands, demonstrating strong market demand and execution [3][5] - The strategic shift allows Prenetics to focus entirely on high-growth consumer health business [5] Bitcoin Treasury Strategy - Prenetics holds 255.4 BTC, valued at $31.6 million, with an unrealized profit of $3.86 million, reflecting a 13.9% return on investment [4][7] - The company has implemented a disciplined strategy of purchasing 1 BTC daily since August 2025, with all holdings securely custodied at Kraken [4][7] - Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption through its Bitcoin treasury strategy [6]